Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | XDH | P47989 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | GFER | P55789 | 1/20 | 0.55 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.55 |
| ▸ | RELA | Q04206 | 1/20 | 0.55 |
| ▸ | FUT7 | Q11130 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | CNR2 | P34972 | 2/20 | 0.54 |
| ▸ | CA12 | O43570 | 3/20 | 0.53 |
| ▸ | CA1 | P00915 | 3/20 | 0.53 |
| ▸ | CA2 | P00918 | 3/20 | 0.53 |
| ▸ | CA7 | P43166 | 3/20 | 0.53 |
| ▸ | CA9 | Q16790 | 3/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.53 |
| ▸ | PKM | P14618 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Syringate SCHEMBL159392 | 0.88 | CA12 (0.67) | KDM4ELMNAGAAXDHPOLB | |
| SCHEMBL198717 | 0.86 | KDM4E (0.65) | KDM4ELMNAGAAXDHPOLB | |
| SCHEMBL30594704 | 0.85 | KDM4E (0.77) | KDM4ELMNAGAAXDHPOLB | |
| SCHEMBL1465618 | 0.85 | KDM4E (0.77) | KDM4ELMNAGAAXDHPOLB | |
| SCHEMBL2308812 | 0.84 | HSD17B2 (0.62) | KDM4ELMNAGAAPOLBCA12 | |
| SCHEMBL12396894 | 0.83 | LMNA (0.78) | KDM4ELMNAGAACA12CA1 | |
| SCHEMBL18969524 | 0.83 | KMT2A (0.51) | KDM4ELMNAGAAXDHPOLB | |
| SCHEMBL17655667 | 0.83 | KDM4E (0.57) | KDM4ELMNAGAAXDHPOLB | |
| SCHEMBL3230514 | 0.83 | CA12 (0.78) | KDM4ELMNAPOLBFUT7TDP1 | |
| SCHEMBL24425750 | 0.81 | KMT2A (0.54) | KDM4ELMNAPOLBCNR2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10995084-B2 | Pyrrolidine derivative | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2021-05-04 | — | — | US | disclosed |
| CN-109476639-B | Pyrrolidine derivatives | 橘生药品工业股份有限公司 | 2021-02-26 | — | — | CN | disclosed |
| US-20200299273-A1 | PYRROLIDINE DERIVATIVE | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2020-09-24 | — | — | US | disclosed |
| EP-3459941-A1 | PYRROLIDINE DERIVATIVE | Kissei Pharmaceutical Co., Ltd. (JP) | 2019-03-27 | — | — | EP | disclosed |
| US-20180020708-A1 | GLUCOSYRINGIC ACID ANALOGS AS SWEETNESS PROFILE MODIFIERS | PEPSICO, INC. | 2018-01-25 | — | — | US | disclosed |
| US-20120021061-A1 | MEDICAL AND NUTRITIONAL FORMULATIONS | COMVITA NEW ZEALAND LIMITED (NZ) | 2012-01-26 | — | — | US | disclosed |
| US-8101774-B2 | Ester derivatives and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2012-01-24 | — | — | US | disclosed |
| US-8101774-B2 | Ester derivatives and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2012-01-24 | — | — | US | disclosed |
| US-8101774-B2 | Ester derivatives and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2012-01-24 | — | — | US | disclosed |
| US-20110287059-A1 | HONEY ANALYSIS | COMVITA NEW ZEALAND LIMITED (NZ) | 2011-11-24 | — | — | US | disclosed |
| EP-1803452-A1 | ESTER DERIVATIVE AND PHARMACEUTICAL USE THEREOF | Japan Tobacco, Inc. (JP) | 2007-07-04 | — | — | EP | disclosed |
| EP-1803452-A1 | ESTER DERIVATIVE AND PHARMACEUTICAL USE THEREOF | Japan Tobacco, Inc. (JP) | 2007-07-04 | — | — | EP | disclosed |
| US-20060089392-A1 | Ester derivatives and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2006-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299273-A1 | PYRROLIDINE DERIVATIVE | CALCRL, NPY1R, GRPR | KDM4E 2084/4885LMNA 2746/4885GAA 3678/4885 |
| US-10995084-B2 | Pyrrolidine derivative | CALCRL, NPY1R, GRPR | KDM4E 2084/4885LMNA 2746/4885GAA 3678/4885 |
| US-20120021061-A1 | MEDICAL AND NUTRITIONAL FORMULATIONS | FABP6, NNT, IAPP | KDM4E 2175/4885LMNA 2820/4885GAA 565/4885 |
| US-20110287059-A1 | HONEY ANALYSIS | GLO1, GLMN, AGER | KDM4E 709/4885LMNA 2071/4885GAA 312/4885 |
| US-20180020708-A1 | GLUCOSYRINGIC ACID ANALOGS AS SWEETNESS PROFILE MODIFIERS | GPR119, TAS2R42, TAS2R31 | KDM4E 3235/4885LMNA 3784/4885GAA 184/4885 |
| US-20060089392-A1 | Ester derivatives and medicinal use thereof | MTTP, CETP, LIPA | KDM4E 2908/4885LMNA 2858/4885GAA 312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.